价值大师评分 :
0
/100
1月
3月
6月
今年
1年
3年
5年
10年
15年
全部
3年:0%
Prenetics Global Ltd 安全边际 ％：每股收益折现模型 : 无意义％ (今日)
* 除每股数值，比率，百分比，其他数据单位均为百万。数据的货币单位均为当地股票的交易货币单位。
Prenetics Global Ltd安全边际 ％：每股收益折现模型（Margin of Safety % (DCF Earnings Based)）的相关内容及计算方法如下：
安全边际 ％：每股收益折现模型 =（ 内在价值：每股收益折现模型 - 当前股价）/ 内在价值：每股收益折现模型
注意：DCF计算器的相关指标仅适用于可预测的公司（即公司的 可预测性评级 高于1颗星）。当公司 可预测性评级 为1颗星，或者没有评级的时候，DCF计算器的结果可能并不准确，因而相关指标不会被写入数据库。
Prenetics Global Ltd的 可预测性评级 为 没有评级。因此您在筛选器和自选列表中看到的DCF相关结果会是0。
Prenetics Global Ltd 安全边际 ％：每股收益折现模型 （PRE 安全边际 ％：每股收益折现模型） 相关词条
感谢查看价值大师中文站为您提供的Prenetics Global Ltd安全边际 ％：每股收益折现模型的详细介绍，请点击以下链接查看与Prenetics Global Ltd安全边际 ％：每股收益折现模型相关的其他词条：
Prenetics Global Ltd （PRE） 公司简介
一级行业：医疗保健
二级行业：医疗诊断和研究
公司网站：https://www.prenetics.com
公司地址：Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
公司简介：Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.
二级行业：医疗诊断和研究
公司网站：https://www.prenetics.com
公司地址：Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
公司简介：Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.